Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editorial staff interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

Orthopedic surgery, as we know it, is undergoing a revolution. Saws, hammers, screws, pins, and metal rods are beginning to give way to growth factors, stem cells, gene therapy, and tissue engineered products. In other words, molecular medicine ultimately will transform orthopedic surgery.

One of leaders at the forefront of this paradigm shift is Dr. Thomas Einhorn, chairman of the department of orthopedic surgery and professor of orthopedic surgery, biochemistry, and biomedical engineering at Boston University.

During this week's GEN podcast, Dr. Einhorn talks about how the increasing use of biologics is changing the practice of surgery. He discusses some of the major advantages that biologics such as recombinant proteins enjoy over standard surgical tools. Dr. Einhorn provides current examples of where biologics are already having an impact in surgical procedures, including those he has carried out himself.

Dr. Einhorn also goes over the key obstacles biologic-related approaches must overcome before they become more common in operating rooms. He also looks at those biologic techniques that appear to be most promising long-term.

Thomas Einhorn, M.D. A graduate of Rutgers University and Cornell Medical College, Dr. Einhorn completed his internship at the Hospital of the University of Pennsylvania, orthopaedic residency at St. Luke's-Roosevelt Hospital in New York City, and a fellowship at the Hospital for Special Surgery. His professional interests include research on the repair and regeneration of bone and cartilage, reconstructive surgery of the hip and knee, and the treatment of metabolic bone disease. He has served as Chairman of the Orthopaedics and Musculoskeletal Study Section of the National Institutes of Health, President of the Orthopaedic Research Society, President of the International Society for Fracture Repair and Chairman of the Committee on Examinations of the American Academy of Orthopaedic Surgeons. Currently, he is a trustee of the Orthopaedic Research and Education Foundation and the National Osteoporosis Foundation. His awards include the American British Canadian Travelling Fellowship, Marshall R. Urist Award, and Kappa Delta Award. His editorial posts include Deputy Editor for Current Concepts Reviews for The Journal of Bone and Joint Surgery, and membership on the Editorial Boards of The Journal of Bone and Mineral Research, Jouranl of Orthopaedic Research and Bone. Since 1997, he has been listed as one of the Best Doctors in America. An author of over 130 scientific articles, his future goals are dedicated to exploring the role of molecular medicine in orthopaedic surgery.

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »